ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2357

Confounding By Indication Distorts The Relationship Between Steroid Use and Cardiovascular Disease In Rheumatoid Arthritis

Alper M. van Sijl1, Maarten Boers2, Alexandre E. Voskuyl1 and Mike T. Nurmohamed1, 1Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 2Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, Confounding, Epidemiologic methods, rheumatoid arthritis (RA) and steroids

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy III

Session Type: Abstract Submissions (ACR)

Background/Purpose: Glucocorticoids (GC) are among the most effective drugs in rheumatoid arthritis (RA), but concerns over long-term side effects have not been resolved. Recent studies indicate that cumulative exposure to GC is associated with an increased risk of cardiovascular (CV) disease, perhaps in part through worsening of the CV risk profile. However, GC also strongly decrease inflammation in RA, and inflammation also has an etiological role in the increased CV risk in this group. The net effect of GC use on CV risk in RA therefore remains unknown.

Methods: RA patients aged 50-75 years were followed for approximately 10 years to study the development of CV disease in the Cardiovascular Risk in RhEumatoid arthritis (CARRE) study. This study was the first to report that CV disease incidence in RA was equal to diabetes mellitus. For the current study, GC exposure was characterized by duration, last exposure by date, the mean dose of GC and cumulative exposure in grams. Data collection included traditional CV risk factors and RA-related parameters and disease activity. Cox proportional hazard analysed the association between GC exposure and incident CV disease, with adjustment for confounders.

 

Results: The study comprised 353 individuals of whom 59 (17%) were exposed to GC at the time of inclusion, with a median (interquartile range) the cumulative exposure was 8.7 (2.5-25.4) grams. After a total follow-up experience of 2361 years, 58 (17%) participants developed incident CV disease, yielding an incidence rate of 24.6/1.000 patient years. Incident cases were more frequently treated with GC at baseline than RA patients without CV disease (22 vs. 16%, p-value 0.089), were treated with GC for a longer period (4.1 vs. 1.9 years, p-value 0.090) and cumulatively used more GC (31.9 vs. 8.5 grams, p-value 0.046). These differences remained after adjustment for demographics and CV risk. However, additional adjustment for at baseline measured 28-joint disease activity score (DAS28) and disability (Health Assessment Questionnaire, HAQ) completely erased the associations of GC with incident CV disease. These observations appear robust and unaffected by power constraints, as the standard errors of the beta estimates remained essentially similar after adjustment.

 

Conclusion: It appears that GC use in uncontrolled populations represents a marker of high RA disease activity; high disease activity itself represents an increased risk of CV disease. Thus the observed relationship of GC with CV disease in RA patients is strongly confounded by indication, as suggested by the adjusted analyses. In this setting, it is possible that the adverse CV effects of GC are balanced by positive effects working through inflammation control.

Figure. Kaplan-Meier survival curves


Disclosure:

A. M. van Sijl,
None;

M. Boers,
None;

A. E. Voskuyl,
None;

M. T. Nurmohamed,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/confounding-by-indication-distorts-the-relationship-between-steroid-use-and-cardiovascular-disease-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology